BOEHRINGER-INGELHEIM
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.
In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past years, the real world results are poor, and there are no or only limited treatment options in many areas, resulting in an overall high unmet need. The collaboration between Boehringer Ingelheim and Inflammasome aims to address this challenge by using Inflammasome’s technology to deliver therapeutics in a biodegradable gel formulation into the eye.
“We are delighted to enter into a collaboration with a company of Boehringer Ingelheim’s stature,” said Paul Ashton, Chief Executive Officer of Inflammasome Therapeutics. “We look forward to working with their team to leverage our respective technologies and expertise to develop new therapies for devastating retinal diseases leading to blindness. This collaboration fits our strategy of advancing the company via both collaborations and internal development.”
“Boehringer Ingelheim is looking forward to developing Inflammasome’s novel technology for the delivery of our first-in- class retinal disease compounds working jointly with Inflammasome’s highly experienced scientific team,” said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This will enable us to develop a broad range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy options.”
Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. Inflammasome’s novel delivery technology using a long-acting degradable IVT implant complements this portfolio.
Inflammasome is entitled to receive up to $160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.
Please click on the link for ´Notes to Editors´and ´References´:
http://www.boehringer-ingelheim.com/press-release/collaboration-novel-therapies-retinal-diseases
View source version on businesswire.com: https://www.businesswire.com/news/home/20190920005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Acquires Thru, Inc., Strengthening Secure Managed File Transfer (MFT) and Advancing Context-Aware Integration15.5.2025 15:00:00 CEST | Press release
Acquisition enhances Boomi’s MFT capabilities, unifying API, application, and file-based data movement within a single platform Boomi™, the leader in AI-driven automation, today announced a definitive agreement to acquire Thru, Inc., a provider of enterprise-grade Managed File Transfer solutions and trusted Boomi partner. The acquisition marks a strategic expansion of Boomi’s file-based integration capabilities, all within a single, cloud-native platform that seamlessly manages data movement across APIs, applications, and files. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515314260/en/ Boomi Acquires Thru, Inc., Strengthening Secure Managed File Transfer (MFT) and Advancing Context-Aware Integration “As organizations increasingly manage a hybrid mix of API-based and file-based integrations, Thru, Inc.’s proven MFT technology ensures secure, scalable, and compliant file exchange across distributed business ecosystems,”
New York Mobile Becomes First U.S. MVNO to Launch on Telness Tech’s Seamless OS15.5.2025 15:00:00 CEST | Press release
New York Mobile is the first U.S. mobile virtual network operator (MVNO) to launch using Telness Tech’s newly launched Seamless OS platform. This deployment enables NY Mobile to deliver a next-generation wireless service, on T-Mobile’s largest and fastest 5G network. NY Mobile will be able to offer unprecedented features and flexibility for its customers including a vanity phone number marketplace and create-your-own-plan options. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515669016/en/ from the left; Jonas Cedenwing (Founder & CTO Telness Tech) Giovanni Perone, Co-Founder & CEO at New York Mobile. Location; One World Trade Center (NY Mobile HQ). Photo taken by Sebastian Stecki. Customers can search and claim personalized phone numbers (including exclusive, previously exhausted area codes, creative number patterns, and words) through New York Mobile’s one-of-a-kind vanity number search engine and marketplace. This mak
Advanced Technologies Enable Reuse of 18.1 Billion Cubic Meters of Water15.5.2025 14:00:00 CEST | Press release
New report shows how utilities and businesses around the world are reusing water, preventing water loss, and creating more water-secure communities Utilities and businesses around the world have reused 18.1 billion cubic meters of water since 2019, enabled by solutions from global water technology leader Xylem (NYSE: XYL), the Company revealed in its most recent Sustainability Report. That volume is enough to meet the annual water needs of more than 350 million people, based on global use estimates.1 Reuse is just one part of a broader effort to increase global water security – alongside the implementation of advanced treatment and digital technologies. Water managers are using the innovations to protect water sources, remove contaminants, reduce emissions, and make water infrastructure more resilient. “Our customers are tackling the world’s toughest water challenges,” said Matthew Pine, Xylem President and Chief Executive Officer. “Their results show the impact of scaling proven techn
Rubicon Carbon Enters into Agreement with Microsoft for Nature-based Carbon Removal Credits15.5.2025 14:00:00 CEST | Press release
This initiative marks one of the largest-ever commitments by a single corporate buyer in the voluntary carbon market to date. Rubicon Carbon, a leading carbon credit management firm, today entered into a framework agreement with Microsoft to facilitate the purchase of 18 million tonnes of high-quality carbon removal credits – one of the largest single-buyer commitments of its kind in the world. Each carbon removal transaction under this deal will be structured as 15- to 20-year offtakes, supporting a pipeline of individual Afforestation, Reforestation, and Revegetation (ARR) projects worldwide. A defining feature of this framework agreement is the scale of Microsoft’s work in this space. By anchoring long-term offtake agreements, this deal demonstrates the growing role of corporate buyers in unlocking private investment for high-integrity carbon projects that might otherwise lack funding. “Addressing climate change requires more than good intentions—it requires capital deployment at sc
Horizon3.ai Gains FedRAMP High Authorization, Delivering on Its Commitment to Secure the Public Sector15.5.2025 14:00:00 CEST | Press release
Horizon3.ai, the global leader in offensive security, today announced it has gained Federal Risk and Authorization Management Program (FedRAMP®) High Authorization, unlocking the ability to support even the most security-sensitive federal missions. This milestone fulfills Horizon3.ai’s previously announced commitment to bring proof-based security to government agencies operating at the highest levels of compliance and risk exposure. Horizon3.ai’s newly authorized platform, NodeZero Federal™, is now available to federal agencies under the FedRAMP High baseline. Built upon the proven commercial version of the NodeZero® Offensive Security Platform, NodeZero Federal™ is designed specifically to meet the heightened security and compliance demands of government environments. With this authorization in place, Horizon3.ai becomes the first and only cybersecurity vendor authorized to deliver continuous, autonomous pentesting within this strict regulatory framework. “We built NodeZero to help de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom